These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 16861053

  • 1. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.
    Markowitz J, Hyams J, Mack D, Leleiko N, Evans J, Kugathasan S, Pfefferkorn M, Mezoff A, Rosh J, Tolia V, Otley A, Griffiths A, Moyer MS, Oliva-Hemker M, Wyllie R, Rothbaum R, Bousvaros A, Del Rosario JF, Hale S, Lerer T, Pediatric IBD Collaborative Research Group.
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1124-9. PubMed ID: 16861053
    [Abstract] [Full Text] [Related]

  • 2. The natural history of corticosteroid therapy for ulcerative colitis in children.
    Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, Otley A, Evans J, Pfefferkorn M, Rosh J, Rothbaum R, Kugathasan S, Mezoff A, Wyllie R, Tolia V, delRosario JF, Moyer MS, Oliva-Hemker M, Leleiko N, Pediatric Inflammatory Bowel Disease Collaborative Research Group.
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1118-23. PubMed ID: 16820327
    [Abstract] [Full Text] [Related]

  • 3. A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn's disease.
    Cullen G, Keegan D, Mulcahy HE, O'Donoghue DP.
    Clin Gastroenterol Hepatol; 2009 Mar; 7(3):323-8; quiz 252. PubMed ID: 19174193
    [Abstract] [Full Text] [Related]

  • 4. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms.
    Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J.
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):168-74. PubMed ID: 19179878
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort.
    Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J.
    Aliment Pharmacol Ther; 2006 Jul 15; 24(2):319-30. PubMed ID: 16842459
    [Abstract] [Full Text] [Related]

  • 6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 15; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 7. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 15; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 8. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec 15; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 9. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G, Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club.
    Gastroenterology; 2010 Feb 15; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [Abstract] [Full Text] [Related]

  • 10. Outcome following infliximab therapy in children with ulcerative colitis.
    Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Grossman A, Tomer G, Kay M, Crandall W, Oliva-Hemker M, Keljo D, LeLeiko N, Markowitz J, Pediatric Inflammatory Bowel Disease Collaborative Research Group.
    Am J Gastroenterol; 2010 Jun 15; 105(6):1430-6. PubMed ID: 20104217
    [Abstract] [Full Text] [Related]

  • 11. Infliximab treatment for symptomatic Crohn's disease strictures.
    Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC.
    Aliment Pharmacol Ther; 2009 Feb 01; 29(3):279-85. PubMed ID: 19035967
    [Abstract] [Full Text] [Related]

  • 12. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
    Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ.
    Am J Gastroenterol; 2006 May 01; 101(5):1030-8. PubMed ID: 16606351
    [Abstract] [Full Text] [Related]

  • 13. Infliximab dependency in children with Crohn's disease.
    Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, Elkjaer M, Andersen PS, Vitek L, Larsen K, Lukas M, Nevoral J, Wewer V, Munkholm P.
    Aliment Pharmacol Ther; 2009 Apr 01; 29(7):792-9. PubMed ID: 19183163
    [Abstract] [Full Text] [Related]

  • 14. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M, Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives.
    Gastroenterology; 2012 Jan 01; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease.
    Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Mamula P, Kay M, Crandall W, Oliva-Hemker M, Keljo D, LeLeiko N, Markowitz J, Pediatric Inflammatory Bowel Disease Collaborative Research Group.
    Inflamm Bowel Dis; 2009 Jun 01; 15(6):816-22. PubMed ID: 19107783
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
    Bermejo F, López San Román A, Algaba A, van Domselaar M, Carneros JA, Rivero M, Piqueras B, Valer MP.
    Gastroenterol Hepatol; 2008 Dec 01; 31(10):629-32. PubMed ID: 19174078
    [Abstract] [Full Text] [Related]

  • 17. Corticosteroid-sparing treatments in patients with Crohn's disease.
    Plevy SE.
    Am J Gastroenterol; 2002 Jul 01; 97(7):1607-17. PubMed ID: 12135008
    [Abstract] [Full Text] [Related]

  • 18. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B.
    Aliment Pharmacol Ther; 2009 Aug 01; 30(3):253-64. PubMed ID: 19438424
    [Abstract] [Full Text] [Related]

  • 19. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
    Gisbert JP, Panés J.
    Am J Gastroenterol; 2009 Mar 01; 104(3):760-7. PubMed ID: 19174781
    [Abstract] [Full Text] [Related]

  • 20. Infliximab for ulcerative colitis in children and adolescents.
    McGinnis JK, Murray KF.
    J Clin Gastroenterol; 2008 Sep 01; 42(8):875-9. PubMed ID: 18645529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.